Hsbc Holdings PLC Sells 22,118 Shares of Progyny, Inc. $PGNY

Hsbc Holdings PLC reduced its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 53.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,206 shares of the company’s stock after selling 22,118 shares during the quarter. Hsbc Holdings PLC’s holdings in Progyny were worth $327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. State Street Corp boosted its position in shares of Progyny by 1.5% during the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock worth $75,838,000 after acquiring an additional 44,642 shares during the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in Progyny by 46.9% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after acquiring an additional 859,289 shares in the last quarter. Wellington Management Group LLP increased its holdings in Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after acquiring an additional 1,621,688 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Progyny by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock worth $50,655,000 after purchasing an additional 20,533 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

PGNY stock opened at $31.13 on Monday. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $33.06. The company has a 50-day moving average price of $28.55 and a 200 day moving average price of $23.22. The stock has a market cap of $2.44 billion, a PE ratio of 40.43, a P/E/G ratio of 2.47 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm’s revenue for the quarter was down 26.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Sell-side analysts forecast that Progyny, Inc. will post 1.19 EPS for the current year.

Progyny declared that its board has approved a share buyback program on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 10.3% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research firms have commented on PGNY. Wall Street Zen downgraded shares of Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Citizens Jmp lifted their target price on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Monday, May 11th. Canaccord Genuity Group boosted their target price on Progyny from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Truist Financial raised their price target on Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Finally, Weiss Ratings raised Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.25.

Insider Activity

In related news, Director Cheryl Scott sold 7,439 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $26.39, for a total transaction of $196,315.21. Following the completion of the transaction, the director owned 19,772 shares in the company, valued at $521,783.08. The trade was a 27.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kevin K. Gordon sold 5,500 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total value of $137,445.00. Following the completion of the transaction, the director directly owned 9,318 shares in the company, valued at $232,856.82. This trade represents a 37.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 36,916 shares of company stock valued at $939,875. 9.90% of the stock is currently owned by corporate insiders.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.